Gliomas are the most frequent primary brain tumors. In a minority of cases, the differentiation between astrocytomas and oligodendrogliomas based on morphologic characteristics alone can be difficult; though it is important, as patients with oligodendrogliomas follow a more favorable clinical course. Here we report on the immunohistochemical expression pattern of the oligodendrocytic marker Nogo-A in 113 central nervous system tumors including 28 oligodendrogliomas [15, World Health Organization (WHO) grade II; 13, grade WHO III], 50 astrocytomas [10, grade WHO II; 11, grade WHO III; 29 glioblastoma multiforme (GBM)], 11 ependymomas WHO grade II, 7 central neurocytomas, 2 dysembryoplastic neuroepithelial tumors (DNTs), 5 clear cell meningiomas, and 10 metastases to the brain. The oligodendrocytic marker Nogo-A was found to be strongly expressed in 71% of oligodendrogliomas, but in 0% of ependymomas WHO grade II, astrocytomas WHO grade II or III, DNTs, central neurocytomas, or clear cell meningiomas. In GBM, a subgroup of tumors (24%) showed strong expression of Nogo-A coincidently with Ki67 positivity but glial fibrillary acidic protein-negativity. However, neither in oligodendrogliomas nor GBM was a correlation between the loss of 1p19q and the extent of Nogo-A expression observed. Our findings indicate that Nogo-A is strongly expressed in the majority of oligodendrogliomas and might be a helpful marker to distinguish oligodendrogliomas from astrocytomas WHO grades II and III as well as ependymomas. They also support the hypothesis that GBM may be a heterogeneous group of tumors derived from different progenitor cells.
D iffuse gliomas account for 78% of all malignant central nervous system (CNS) tumors. The majority of gliomas are classified as either astrocytomas (70% to 75%) or oligodendrogliomas (12% to 20%), or less frequently as oligoastrocytomas (5% to 10%). 12 Differential diagnosis between these entities is of clinical importance to determine the optimal treatment protocol. Among diffuse gliomas, oligodendrogliomas have the best prognosis and cases which are cytogenetically characterized by loss of chromosomes 1p and 19q show a prolonged progression-free interval after combined radiotherapy and chemotherapy. 4, 34 Differentiating between oligodendroglial and astrocytic tumors can be challenging and in some instances morphologic criteria alone are not sufficient to establish an unequivocal diagnosis. For this purpose, a specific oligodendroglial marker would be of certain value. However, immunohistochemical oligodendroglial markers, such as anti-CNP (2 0 , 3 0 -cyclic nucleotide 3 0 -phosphodiesterase) antibody and anti-tubulin polymerization promoting protein/p25 antibody or in situ hybridization with a proteolipid protein mRNA probe identify only oligodendrocytes in healthy CNS tissue but not oligodendroglial tumor cells. 20, 25, 31 Therefore, we conducted an immunohistochemical study on a larger series of CNS tumors to determine whether Nogo-A, a marker expressed in mature oligodendrocytes, is suitable for distinguishing oligodendroglial from other CNS tumors, especially from morphologically related low-grade astrocytomas.
Nogo-A and its splice variants Nogo-B and -C belong to the reticulon family, the members of which all share a common C-terminus of 200 bp. Nogo-A is strongly expressed in oligodendrocytes and to a weaker extent in myelin sheaths and some neuronal populations. 3, 10, 13, 35 Nogo-A prevents axonal regrowth and sprouting. 5, 8, 26 In addition, Nogo-B has been found to be expressed in different cancer cell lines. 14, 21 Overexpression of Nogo-B as well as Nogo-C induces apoptosis and both splice variants are known to interact with other apoptosis-related proteins including, bcl-2, bcl-xL, and drs. 6, 32, 33 The function of the Nogo-A in glial tumors, however, is so far unknown.
In this study, we found Nogo-A to be strongly expressed in 71% of grade II and III oligodendrogliomas. In contrast, clearly fewer Nogo-A-positive cells were found in astrocytomas World Health Organization (WHO) grade II, astrocytomas WHO grade III, ependymomas, dysembryoplastic neuroepithelial tumors (DNTs), central neurocytomas and clear cell meningiomas. In glioblastoma multiforme (GBM), 24% of the tumors showed a strong expression of Nogo-A, but no colocalization of Nogo-A with the astrocytic marker glial fibrillary acidic protein (GFAP) was observed. Nogo-A-positive cells proliferated as shown by double immunohistochemistry with the proliferation marker Ki67 in GBM. However, no correlation between Nogo-A expression and loss of 1p and 19q was found in oligodendrogliomas or GBM.
Our data demonstrate that the oligodendroglial marker Nogo-A is strongly expressed in the majority of oligodendrogliomas and in a subset of GBMs.
MATERIALS AND METHODS

Tumor Samples
One hundred thirteen paraffin-embedded surgical tumor specimens were selected for this study. Tumors were diagnosed according to the WHO classification. Fifty tumors were astrocytic tumors (10 astrocytomas WHO grade II, 11 astrocytomas WHO grade III, and 29 GBM). Twenty-eight tumors were oligodendrogliomas (15 oligodendrogliomas WHO grade II and 13 WHO grade III). Furthermore, we analyzed 11 ependymomas (among them 3 clear cell ependymomas) (WHO II), 2 DNTs, 7 central neurocytomas, 5 clear cell meningiomas, and 10 brain metastases from non-CNS carcinomas. The histology of the tumors was reviewed independently by 2 neuropathologists (T.K. and W.B.), according to the current WHO classification. Only tumor specimens displaying typical morphologic characteristics were selected for this study. The neuropathologic examination and the molecular genetic analysis were approved by the local ethics committee and carried out according to the national ethical guidelines and legal regulations.
Immunohistochemistry
After deparaffinization intrinsic peroxidase activity of tumor specimens was blocked by incubation with 5% H 2 O 2 in phosphate-buffered saline for 20 minutes. Nonspecific antibody binding was inhibited with 10% fetal calf serum in phosphate-buffered saline for 25 minutes. The primary antibodies were rabbit anti-Nogo-A (Chemicon, 1:750), mouse anti-Nogo-A (11C7; 1:15,000) (a generous gift from M.E. Schwab, Brain Research Institute, University of Zu¨rich and Department of Biology, Swiss Federal Institute of Technology Zu¨rich, Switzerland), rabbit anti-Olig2 (IBL, Hamburg, Germany; 1:300), and mouse anti-2 0 , 3 0 -cyclic nucleotide 3 0 -phosphodiesterase (anti-CNPase, Sternberger Monoclonals, MD; 1:200). Immunohistochemical staining was performed with an avidin-biotin technique. For double immunohistochemistry, mouse anti-Nogo-A (11C7), polyclonal rabbit anti-Nogo-A, rabbit anti-Olig2, rabbit anti-GFAP antibody (Dako, Glostrup, Denmark; 
Grading of Nogo-A and Olig2 Expression in Tumors
To quantify the numbers of Nogo-A-positive and Olig2-positive cells a semiquantitative score was used. Score 0 (no expression), no positive cells; score 1 (moderate expression), single or group of positive cells; and score 2 (strong expression), more than 50% positive cells. Examples of this grading scheme are shown in Figure 1 .
Comparative Genomic Hybridization
For comparative genomic hybridization (CGH) analysis, tumor DNA was isolated from formalin-fixed and paraffin-embedded tumor tissue sections by proteinase K digestion (2 mg/mL final concentration; Roche, Mannheim, Germany) followed by spin column purification (Qiagen, Hilden, Germany). Labeling of tumor DNA with biotin-16-dUTP (Roche; Mannheim, Germany) and normal reference DNA with digoxigenin-11-dUTP (Roche) was performed by standard nick translation. The denatured DNA probe containing 2 mg of tumor DNA, 1.5 mg of reference DNA, and 80 mg of COT-1 DNA was hybridized for 3 days to normal metaphase spreads on glass slides (15 Â 15 mm cover glass area). The slides were then washed, blocked with bovine serum albumin solution, and incubated with fluoresceinconjugated avidin (Vector Laboratories, Burlingame, CA) and rhodamine-conjugated antidigoxigenin (Roche). Finally, the slides were washed and mounted in antifade solution (Vector Laboratories) containing 2.5 mg/mL 4 0 ,6diamidino-2-phenylindole counterstain. Image acquisition was performed on a Zeiss Axioskop fluorescence microscope (Zeiss, Go¨ttingen, Germany) equipped with 3 separate bandpass filters (4 0 ,6-diamidino-2-phenylindole bandpass, green single bandpass, red single bandpass) and a high-sensitivity monochrome charge coupled device camera (Photometrics, Tuscon, AZ). For each analysis, the averaged chromosome-specific green-to-red fluorescence ratios and their 95% confidence intervals from at least 15 well-selected metaphases were plotted using the Quips CGH software (distributed through Applied Imaging, Newcastle, UK). Relative copy number changes were interpreted as gains when the average green-to-red ratio exceeded 1.2 or 2 (high-level amplification), and losses when the corresponding ratio was less than 0.8. Chromosomal regions 1p32-pter, 13p, 14p, 15p, 21p, 22p, telomeres, and constitutive heterochromatic regions at 1q, 9q, 16q, and Yq reported to produce false results by CGH were excluded from all analyses. 11 CGH analysis failed in 2 oligodendrocytoma WHO grade II which was either owing to low tumor DNA content in the samples or insufficient hybridization.
RESULTS
Nogo-A is Highly Expressed in Oligodendrogliomas
At first, we addressed the question of whether Nogo-A is a suitable marker for oligodendrogliomas. All oligodendrogliomas selected for this study displayed the classic morphologic characteristics of oligodendrogliomas. Mixed oligoastrocytomas were excluded from this study. A semiquantitative score was applied to quantify the number of Nogo-A-positive cells (0, no expression; 1, expression in single cells or group of cells; 2, Z50% positive cells) (Figs. 1A-C).
Nogo-A was strongly (score 2) expressed in 10 of 15 (67%) WHO grade II oligodendrogliomas and in 10 of 13 (77%) WHO grade III oligodendrogliomas and showed a homogenous staining pattern in the majority of oligodendroglial tumors ( Figs. 2A, B , Table 1 ). The remaining oligodendrogliomas WHO grade II and III displayed a moderate Nogo-A expression (score 1) ( Table 1) . Subsequently, we analyzed Nogo-A expression in other glial and clear cell primary CNS tumors as well as metastases to the brain (Figs. 2C-F). All low-grade astrocytomas (10/10, 100%), ependymomas (11/11, 100%), DNTs (2/2), and clear cell meningiomas (5/5) revealed no or only moderate expression (Figs. 2C, D, H, Table 1 ). Out of the 7 neurocytomas, 3 were completely negative for Nogo-A (score 0) whereas the remaining 4 neurocytomas displayed small foci of Nogo-A-positive cells (score 1) ( Fig. 2G ). All of the astrocytomas WHO grade III (11/11, 100%) showed a moderate Nogo-A signal ( Table 1) . The sensitivity and specificity of a strong Nogo-A signal (score 2) to distinguish an oligodendroglioma from an ependymoma, or an astrocytoma WHO grade II or III were 0.71 and 1.0, respectively. Furthermore, the specificity of Nogo-A with regard to recognizing only brain cells from the glial lineage was confirmed by the lack of immunoreactivity in any of the metastases to the brain. We also determined the expression of CNPase, another oligodendroglial marker, in 23 oligodendrogliomas. None of the oligodendrogliomas expressed CNPase, confirming earlier studies. 20, 31 
Nogo-A Expression in GBM
In GBM, Nogo-A expression was heterogenous. A subset of GBMs (7 of 29, 24%) showed a strong Nogo-A signal (score 2), whereas 59% (17 of 29) and 17% (5 of 29) displayed a moderate or absent Nogo-A expression signal, respectively (Figs. 2E, F). In the GBMs with strong Nogo-A expression, large tumor regions with high numbers of Nogo-A-positive cells were observed; however, there were also regions showing few or no Nogo-A-positive cells.
To eliminate the possibility that the Nogo-A-positive tumor cells in GBM were derived from the astrocytic lineage, we performed a double immunohistochemical study using Nogo-A and GFAP antibodies. We analyzed GBM, which were selected by virtue of their Nogo-A expression (score 1 or 2). In 9 of 11 GBM, Nogo-A and GFAP expression was confined to 2 separate cell populations (Figs. 3A-C). The remaining 2 GBMs showed numerous tumor cells that were either positive for Nogo-A or GFAP, but also single tumor cells that coexpressed GFAP and Nogo-A within the same cell (data not shown).
To confirm that the Nogo-A-positive cells were indeed tumor cells, we performed double stainings for Nogo-A and the proliferation marker Ki67 in 14 cases of GBM. A marked number of Nogo-A-positive cells was found to express Ki67 in all examined GBM demonstrating that the Nogo-A-positive cells are proliferating tumor cells ( Figs. 3D-E) . To address the question whether Nogo-A expression and proliferation correlates in GBM, we estimated the proliferation rate in GBM. The proliferation in GBM varied between 3% and 25%; however, no correlation between Nogo-A expression and proliferation rate was observed.
Olig2 Expression in Oligodendrogliomas and GBMs
Olig2 is known to be expressed in oligodendroglial progenitors during development and in the adult CNS. Conflicting results regarding the Olig2 expression in glial Oligodendroglioma III 13  2  nd  Astrocytoma II 1  0  nd  Astrocytoma II 2  1  nd  Astrocytoma II 3  1  nd  Astrocytoma II 4  1  nd  Astrocytoma II 5  1  nd  Astrocytoma II 6  1  nd  Astrocytoma II 7  1  nd  Astrocytoma II 8  1  nd  Astrocytoma II 9  1  nd  Astrocytoma II 10  1  nd  Astrocytoma III 1  1  nd  Astrocytoma III 2  1  nd  Astrocytoma III 3  1  nd  Astrocytoma III 4  1  nd  Astrocytoma III 5  1  nd  Astrocytoma III 6  1  nd  Astrocytoma III 7  1  nd  Astrocytoma III 8  1  nd  Astrocytoma III 9  1  nd  Astrocytoma III 10  1  nd  Astrocytoma III 11  1  nd  Ependymoma II 1  1  nd  Ependymoma II 2  1  nd  Ependymoma II 3  0  nd  Ependymoma II 4  0  nd  Ependymoma II 5  0  nd  Ependymoma II 6  0  nd  Ependymoma II CNS tumors have been published. [15] [16] [17] 19 Therefore, we conducted an Olig2 staining on 13 oligodendrogliomas and 27 GBM. In 4 of 6 (60%) WHO grade II and 6 of 7 (86%) WHO grade III oligodendrogliomas, more than 50% of the tumor cells were Olig2 positive (score 2) (Figs. 4, 5A, 5B). The remaining oligodendrogliomas displayed groups of Olig2-positive cells (score 1). Similar results were obtained in GBM, where all 27 cases were either scored as 1 or 2 and the expression pattern of Olig2 overlapped with that of Nogo-A (Figs. 4, 5C ). The Olig2 staining intensity varied within the same tumor and from tumor to tumor. Comparing the staining for Olig2, GFAP and Nogo-A in consecutive sections of the same tumor region of GBM showed that a subset of Olig2positive cells expressed neither Nogo-A nor GFAP (Figs. 5C-E). Double immunohistochemistry with antibodies directed against Nogo-A and Olig2 revealed that almost all Nogo-A-positive cells were also Olig2 positive. In addition, in GBMs numerous Olig2-positive cells were observed that were Nogo-A negative (Figs. 5C, D, F, G) . To confirm that at least some of the Olig2-positive and Nogo-A-negative cells were astrocytic tumor cells, we subjected 11 GBM, which were characterized by strong Olig2 expression, to an appropriate double immunohistochemistry with anti-Olig2 and anti-GFAP antibodies. Six of the eleven GBM showed groups of astrocytes expressing strongly Olig2 in the nucleus (Figs. 5I-K) . In the other 5 cases, astrocytes were either negative for Olig2 or showed only a weak staining for Olig2 (data not shown).
CGH Analysis
In oligodendrogliomas loss of 1p and 19q is the most frequent event. In this study, loss of 1p and 19q was observed in 7 of 10 successfully analyzed oligodendrogliomas WHO grade II, whereas loss of 1p was observed in 1 oligodendroglioma WHO grade II. In oligodendrogliomas WHO grade III, 4 of 10 tumors revealed loss of 1p and 19q. Among the remaining 6 oligodendrogliomas WHO grade III, one displayed only loss of 1p whereas the other 5 did not show any 1p and/or 19q loss (Table 1) . To address the question of whether GBM demonstrating a higher percentage of Nogo-A-positive cells may show the molecular characteristics of oligodendrogliomas, we performed CGH analysis on 27 glioblastomas characterized by a strong Nogo-A expression in 7 cases and no or moderate expression in 5 or 15 cases, respectively. None of these GBM was marked by loss of 1p and 19q (Table 1) .
DISCUSSION
In this report, we demonstrate that Nogo-A, which is a marker known to be highly expressed in oligodendrocytes, recognizes specifically subsets of glial tumors. Nogo-A was strongly expressed in most of oligodendrogliomas, which contrasts the moderate, or lacking expression in astrocytomas WHO grade II or III and ependymomas. Furthermore, we found that in GBM Nogo-A was strongly expressed in a subset of tumors and that these Nogo-A-positive cells were proliferating tumor cells.
Owing to the fact that a correct diagnosis has immediate consequences for the treatment of glial tumors, more objective diagnostic criteria are required, in addition to the morphologically defined WHO criteria. 4, 12, 34 To date, no immunohistochemical marker exists that allows a definitive distinction to be made between astrocytomas and oligodendrogliomas. 20, 31 Different markers have been repeatedly evaluated in oligodendrogliomas. However, oligodendrogliomas were found to be negative for markers such as MAG, proteolipid protein, or CNP, which are expressed in mature oligodendrocytes under physiologic conditions. 20, 31 Other markers such as Olig2, Nkx2.2, platelet-derived growth factor receptor a, and NG2, which are used to identify more immature oligodendroglial progenitor cells, are rather unspecific for distinguishing oligodendrogliomas from astrocytomas, as they are expressed in both; although the amount is lower in astrocytomas than in oligodendrogliomas. 18, 28, 30 These studies are in line with our findings. Although expression of CNPase was absent in oligodendrogliomas, Olig2 was expressed in all glial tumors examined in this study. In contrast, Nogo-A was found to be expressed strongly in the majority of oligodendrogliomas and in normal oligodendrocytes. In the majority of glial tumors, the Nogo-A expression pattern in oligodendrogliomas was easy to distinguish from that in astrocytomas, ependymomas, and other clear cell primary CNS tumors. In astrocytomas and ependymomas only a moderate number of Nogo-A-positive cells was observed. Whether these cells represent tumor cells or trapped oligodendrocytes remains to be determined. In 4 of 7 central neurocytomas, we found small foci of Nogo-A-positive cells. Interestingly, a recent publication reported the expression of Olig2 in some central neurocytomas. 24 However, Nogo-A is also physiologically weakly expressed in some neuronal populations. Further studies are required to determine the significance of focal Nogo-A expression in central neurocytomas.
Strong Nogo-A expression shows a moderate sensitivity (0.71) and high specificity (1.00) in distinguishing oligodendrogliomas from astrocytomas WHO grade II and III as well as ependymomas. Altogether, these results suggest that strong expression of Nogo-A favors the diagnosis of an oligodendroglioma. However, we did not find a correlation between the extent of Nogo-A expression and the loss of chromosomes 1p and 19q; therefore, determining the extent of Nogo-A expression cannot replace the analysis of the chromosomal status.
Conflicting results are published concerning the expression pattern of Olig2 in glial CNS tumors. The first studies analyzing Olig2 expression in glial tumors described a strong expression of Olig2 in oligodendrogliomas and low or no expression in astrocytomas. 16, 17 More recent studies have reported a wide expression of both Olig2 mRNA and protein in oligodendrogliomas and astrocytomas. 2, 15, 19, 22, 27 We found strong expression of Olig2 in oligodendrogliomas and in glioblastomas, which is similar to findings reported by Ligon et al. 15 In GBM, we found an overlapping expression pattern of Olig2 and Nogo-A cells, given that all Nogo-A-positive cells expressed Olig2 as well but otherwise numerous Olig2-positive cells were negative for Nogo-A. Furthermore, double immunohistochemistry in glioblastomas revealed that a subset of the Olig2-positive cells also expressed GFAP, indicating that the cell type-specific expression of Olig2 in cells of the oligodendroglial lineage observed under physiologic conditions in adult CNS is abolished in GBM.
The origin of GBM has been a matter of debate for a long time. Traditionally, GBM are thought to arise from astrocytes owing to their strong GFAP positivity. In more recent studies the origin of astrocytomas from neural stem cells or neural progenitor cells that can be isolated from GBM has been debated. 7, 29, 36 Astrocytes can give rise to oligodendrogliomas and astrocytomas after gene transfer of polyoma virus middle T antigen. 9 In our study, GBM could be differentiated in 2 subgroups on the basis of their Nogo-A expression. One subgroup was characterized by a strong expression level of Nogo-A (24%) whereas the other subgroup displayed no or moderate Nogo-A expression levels (76%). These findings on GBM which displayed immunohistochemical heterogeneity are in line with recent studies showing that the Olig2 expression in glial CNS tumors. Olig2 was strongly expressed in the majority of oligodendrogliomas WHO II (A) and WHO III (B). In glioblastomas, Olig2 was highly up-regulated as well (C). Panels C to E show the same region of a glioblastoma stained with anti-Olig2 (C), anti-Nogo-A (D) or anti-GFAP (E) antibodies. The presence of Olig2-positive, but Nogo-A and GFAP-negative tumor cells was revealed by comparing the staining patterns of these different markers on consecutive sections. Panels F to H shows the same tumor region of a glioblastoma as (C-E). Almost all Nogo-A-positive cells were also Olig2 positive, but also numerous Olig2-positive cells were detected that did not express Nogo-A (F). A subset of glioblastomas also showed an up-regulation of Olig2 in GFAP-positive tumor cells (I-K). CNS indicates central nervous system; GFAP, glial fibrillary acidic protein; WHO, World Health Organization. oligodendroglial marker Sox10 is highly expressed in only a subset of GBM. 1 Similarly, NG2 and platelet-derived growth factor receptor a expression, which is frequently used to identify oligodendroglial progenitors in normal CNS tissues, can be observed only in a subset of GBM. 30 Furthermore, we could demonstrate that Nogo-A-positive cells in GBM were proliferation active but GFAPnegative, indicating that these Nogo-A-positive cells indeed comprise an own subset of tumor cells. These results might support the hypothesis that glioblastomas are a heterogeneous tumor group that may arise from different types of progenitor cells.
In our study, none of the GBM expressing Nogo-A showed loss of 1p and 19q. Both aberrations are associated with a significantly longer survival time and an increased progression-free survival after combined radiation and chemotherapy in oligodendrogliomas. 4, 34 In morphologically classic anaplastic oligodendrogliomas, loss of 1p and 19q can be observed in 50% to 90% of the cases whereas only about 20% of anaplastic oligoastrocytomas possess this codeletion. 18, 23 Therefore, one might speculate that the Nogo-A-positive GBM without 1p/19q loss as found in our study represent mixed anaplastic oligoastrocytomas with the morphologic features of glioblastomas. As Nogo-A expression does not correlate with 1p19q status neither in oligodendrogliomas nor in astrocytomas, an alternative interpretation could be that tumor cells displaying strong expression of Nogo-A in GBM might be less differentiated tumor cells. Further studies, such as a comparison of the survival time of patients with and without high levels of Nogo-A expression, are required to address this question.
In summary, we show that the oligodendroglial marker Nogo-A is strongly expressed in oligodendrogliomas in contrast to other glial tumors, such as astrocytomas WHO grade II and III and ependymomas.
